Fusion of Spine (Disease) Clinical Trial
Official title:
Clinical Trial to Evaluate the Efficacy and Safety of SurgiFill™ on Spinal Fusion -Comparison Between Autograft Mixed With SurgiFill™ and Autograft in Spinal Fusion-
This study was designed to investigate the safety and efficacy of SurgiFill™, a bone grafting material, in patients with spinal fusion.
Status | Recruiting |
Enrollment | 20 |
Est. completion date | January 2016 |
Est. primary completion date | October 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 20 Years and older |
Eligibility |
Inclusion Criteria: 1. Patients who require spinal fusion 2. Adult patients aged 20 or older 3. Patients who voluntarily agreed to participate in this study and signed the informed consent form, and who do not fall into any of the exclusion criteria Exclusion Criteria: 1. Patients or their family members with a history of an, or an ongoing, autoimmune disease 2. Patients with a history of anaphylactic response 3. Patients with hypersensitivity to grafting materials 4. Patients with hypersensitivity to pig protein 5. Patients with osteomyelitis in the surgery area 6. Patients who are pregnant, breastfeeding, or planning to become pregnant 7. Patients with other tumors or a non-curable disease 8. Patients with a history of radiation therapy or cancer treatment within two years (Those who show normal or insignificant test results may be enrolled in this study and receive the SurgiFill™ injection based on the investigator's judgment.) 9. Patients with diabetes (Those who maintain a normal blood sugar level and did not develop complications may receive the SurgiFill™ injection based on the investigator's judgment, but the doctor's confirmation is required.) 10. Patients with an infection that required hospitalization for antibiotics or the administration of antiseptic agents 11. Patients who have been undergoing adrenocortical hormone therapy (Those who show normal or insignificant test results may be enrolled in this study and receive the SurgiFill™ injection based on the investigator's judgment.) 12. Patients with liver, heart, or kidney disease (Those who show normal or insignificant test results may be enrolled in this study and receive the SurgiFill™ injection based on the investigator's judgment. Hypertension patients are allowed.) 13. Patients who had been infected with a virus (Those who show normal or insignificant test results may be enrolled in this study and receive the SurgiFill™ injection based on the investigator's judgment.) 14. Patients with chronic renal failure or an endocrine system disease (Those who show normal or insignificant test results may be enrolled in this study and receive the SurgiFill™ injection based on the investigator's judgment.) 15. Patients who are considered inappropriate for participation in this study due to their condition (e.g., a mental illness) based on the investigator's judgment 16. Patients who had participated in another clinical trial (limited to those who participated in other studies on fracture within the last six months.) |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | The Catholic Univ. of Korea, Daejeon St. Mary's Hospital | Daejeon | |
Korea, Republic of | The Catholic Univ. of Korea, Seoul St. Mary's Hospital | Seoul |
Lead Sponsor | Collaborator |
---|---|
Sewon Cellontech Co., Ltd. |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Number of abnormal blood test result of participants with adverse events as a measure of safety | Regardless of the clinical trial, if there are blood tests' results of participants with adverse events such as hematologic examination (WBC, RBC, Hemoglobin(Hb), Hematocrit(Hct), Platelet(PLT), ESR) and general chemistry (BUN, Creatinine(Cr), AST, ALT, CRP) closed to the day of regular visit, they shall be recorded on the CRF at screening or after spinal fusion. If there is any abnormality of the results, the number of abnormal blood test result will be recorded, and then additionally the result shall be analyzed according to the investigator's judgment. | up to 12month | Yes |
Primary | Volume change of bony fusion mass in the CT | A CT scan shall be conducted one week, and six and 12 months, post-operatively to calculate and record the bone integration volume. The changes in the bone integration volume shown in the CT images shall be compared and analyzed. In other words, the mean values of the experiment group's bone integration volume shown in CT images 1week, six and 12 months post-operatively shall be compared and analyzed. | 1week, 6month, and 12month | No |
Secondary | Degree change of bony fusion mass in the X-ray | A radiography shall be conducted one, three, six, and 12 months post-operatively, and at the additional unscheduled visits, and the PIs from different institutions (i.e., the Seoul St. Mary's PI and the Daejon St. Mary's PI) shall cross-evaluate the results. The mean values of the experiment group's surgical site bone integration level shown in X-ray images one, three, six and 12 months post-operatively shall be compared and analyzed. | 1month, 3month, 6month, and 12month | No |
Secondary | Value of ROI(Region of interest) in the SPECT/CT | The osteoblastic activity levels at the surgical sites of the experiment and control groups shall be compared at three months post-operatively. | 3month | No |
Secondary | VAS Score change of Back pain questionnaire | The level of the pain (i.e., the lumbar pain and the pain radiating to the upper and lower extremities) shall be recorded using the VAS before the spondylodesis, and at six and 12 months post-operatively. | screening, 6month and 12 month | No |
Secondary | ODI Score change of Back pain questionnaire | Using the ODI score from the ODQ, the disturbances in the daily activities associated with the lumbar pain shall be compared before the spondylodesis, and at six and 12 months post-operatively. | screening, 6month and 12 month | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01750840 -
A Clinical Registry to Collect Patient Outcome Date for the BIOMET® Stimulator Systems
|
N/A | |
Completed |
NCT02485574 -
Anterior Bridging Cage With Bone Substitute Versus Localized Autobone in Transforaminal Lumbar Interbody Arthrodesis
|
N/A | |
Completed |
NCT02890043 -
Clinical Trial for the Application of Tirobot System
|
Phase 3 | |
Completed |
NCT02127060 -
The Effectiveness of Vitamin C in Postoperative Pain Management of Single-level Posterior Lumbar Interbody Fusion (PLIF)
|
N/A |